Compounds > canertinib
Page last updated: 2024-09-04

canertinib and s 1033

canertinib has been researched along with s 1033 in 4 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(s 1033)		Trials
(s 1033)		Recent Studies (post-2010) (s 1033)
1249651,4071471,074

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)s 1033 (IC50)
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)4.7
Solute carrier family 22 member 3Homo sapiens (human)0.5
Tyrosine-protein kinase ABL1Homo sapiens (human)0.34
Low-density lipoprotein receptorHomo sapiens (human)9.8
FibronectinHomo sapiens (human)0.12
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)1.1
Tyrosine-protein kinase LckHomo sapiens (human)0.1082
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.677
Tyrosine-protein kinase LynHomo sapiens (human)1.281
Cytochrome P450 3A4Homo sapiens (human)0.58
Macrophage colony-stimulating factor 1 receptorMus musculus (house mouse)0.534
Platelet-derived growth factor receptor betaHomo sapiens (human)0.052
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1115
Breakpoint cluster region proteinHomo sapiens (human)0.0575
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.01
Solute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)0.042
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)1.0905
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0368
Ephrin type-A receptor 2Homo sapiens (human)0.033
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)9.548
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)4.7
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0371
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.2879
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)4.7
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)4.7
Discoidin domain-containing receptor 2Homo sapiens (human)0.0289
Proprotein convertase subtilisin/kexin type 9Homo sapiens (human)9.8
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.5

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1

Other Studies

4 other study(ies) available for canertinib and s 1033

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022